Sparrow Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sparrow Pharmaceuticals, Inc. - overview
Established
2013
Location
Portland, OR, US
Primary Industry
Biotechnology
About
Based in Oregon, US, and founded in 2013, Sparrow Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The company was founded by Dr. David Katz and is backed by investors including OrbiMed Advisors, RiverVest Ventures, US Venture Partners, and other unspecified investors.
In June 2025, Sparrow Pharmaceuticals, Inc. raised USD 61. 84 million in series B funding co-led by new investors Forbion and RA Capital Management, with participation from returning investors OrbiMed Advisors, RiverVest Ventures Partners, and US Venture Partners. Sparrow Pharmaceuticals provide treatment options for serious disorders of hypercortisolism, autoimmune and inflammatory conditions.
The company also focuses on drug candidates such as SPI-62 and SPI-62 + prednisolone. Sparrow Pharmaceuticals plans to advance its targeted therapy for type 2 diabetes.
Current Investors
OrbiMed Advisors, US Venture Partners, RiverVest Ventures Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.sparrowpharma.com
Verticals
HealthTech, Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.